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Summary. Inflammation is a common pathogenic mechanism involved in many otorhinolaryngological (ORL) 
disorders. Broncalt® is a class II Medical Device containing: thermal water (Medesano, PR, Italy), hyaluronic 
acid, and grapefruit seed extract. It has been reported that it exerted a safe and effective anti-inflammatory, 
washing, and antimicrobial activity by virtue of these components. Therefore, the aim of the current survey, 
conducted in clinical practice of 84 Italian ORL centers, was to evaluate its safety and efficacy in the treat-
ment of patients with acute upper airways disease. The 3,533 (1,797 males, mean age 43.5 years) patients were 
evaluated at baseline (T0) and after a 2-week treatment (T1) with or without Broncalt®. Signs and symptoms 
severity were measured by visual analogue scale. Broncalt® significantly and safely diminished the clinical fea-
tures in all sub-groups (p<0.001 for all). Interestingly, Broncalt® significantly induced a faster symptom relief 
already within 3 days after the start of the treatment. In conclusion, Broncalt® is a class II Medical Device able 
to exert a safe and effective activity in patients with acute ORL disorders. (www.actabiomedica.it)
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O r i g i n a l  a r t i c l e
Introduction
In clinical otorhinolaryngological (ORL) prac-
tice, the airways disorders represent the most frequent 
cause of visit. From a clinical point of view, the res-
piratory ORL diseases may be subdivided in 3 cate-
gories: i) acute illness, including common cold, acute 
rhinosinusitis, acute rhinopharyngitis, acute pharyn-
gitis, acute otitis, bacterial tonsillitis, acute laryngitis 
and acute laryngotracheitis; ii) chronic illness, includ-
*Italian Study Group of inflammatory otorhinolaryngological disorders: Aielli Federica, Albanese Gianluca, Alessi Vincenzo, Allos-
so Giuseppe, Antico Filippo, Antoniacomi Giovanni, Asprea Francesco, Azzaro Raffaele, Azzolina Alfio Alfonso, Benedetto Domenico, 
Bennici Ettore, Berardi Carlo, Bertetto Bruno Ivano, Blotta Pasquale, Bucci Alessandro, Bulzomì Antonio Giovanni, Caligo Giacomo, 
Cantaffa Antonio, Capelli Marco, Casaula Marco, Castagna Giovanni, Castellani Carla, Castellani Francesca, Chiarelli Raffaele, Cia-
battoni Andrea, Colombo Giovanni, Cordier Aldo, Costanzo Marcello, Danza Carlo, De Luca Carlo Maurizio, Degli Innocenti Mas-
simo, D’Emilia Mario, Dessì Roberta, D’Urso Marino, Emanuele Antonino, Falcetti Saverio, Falciglia Roberto, Ferraro Guglielmo, Fini 
Oscar, Franco Teresa, Frascadore Luigi, Fuggetta Alessandro, Gambardella Tullio, Iacolucci Carlo Maria, Ierace Michelangelo, Ingria 
Federico, La Paglia Alessandro, Lavazza Paolo, Leone Mirko, Livi Walter, Londei Salvatore, Lovotti Paolo, Maio Michele, Manis-
calco Francesco, Martone Rosa, Melis Andrea, Mercurio Antonio, Milone Vincenzo, Montanaro Salvatore Carmine, Muià Fernando, 
Mussella Tommaso, Nacci Andrea, Naqe Nertila, Padovani Davide, Palma Antonio, Panetti Maria Luisa, Paoletti Matteo, Pellegrino 
Cataldo, Piccolo Marcello, Pizzolante Maurizio Cosimo, Sari Marianna, Scarpa Alfonso, Scotto di Santillo Leonardo, Serraino Eugenio 
Maurizio, Stabile Carlo, Tatti Maria Fatima, Tauro Francesco, Tombolini Alberto, Turso Giorgio Felice, Zaraca Giorgio
Broncalt®, class II medical device, in patients with acute upper airways disease 25
ing chronic rhinosinusitis, chronic rhinopharyngitis, 
chronic pharyngitis, chronic tonsillitis and chronic lar-
yngitis; and iii) acute-chronic illness, i.e. the chronic 
disease when exacerbates.
Common cold is the most frequent respiratory 
disease and involves entirely the upper respiratory tract, 
it is usually self-limiting (1). The best pragmatic ap-
proach for rhinosinusitis management has been recent-
ly pointed out in clinical practice (2, 3). Alike, pharyn-
gitis, laryngitis, and tracheitis are very common and are 
usually managed as proposed by ad hoc guidelines (4-7). 
Acute ORL diseases may be commonly caused by 
bacterial, viral or fungal aetiology, even though non-
infectious acute disease may also exist. However, infec-
tious illness is the most frequent acute ORL disorders, 
apart allergic and non-allergic rhinitis. The acute in-
fectious diseases share a common pathogenic mecha-
nism: the inflammation. Therefore, the treatment of 
acute airways diseases is targeted to fight both infec-
tion and inflammation, usually using antibiotics and 
anti-inflammatory medications (8-10). These medica-
tions are effective, but antibiotics may be associated 
with bacterial resistance and anti-inflammatory drugs 
may induce serious adverse events. Therefore, the op-
tion of complementary medicine has having even more 
interest by doctors and also patients (11).
In this regard, Broncalt® is a new class II medical 
device containing salso-bromo-iodine thermal water 
(spring of Medesano, PR, Italy) 8%, hyaluronic acid 
(HA) 0.1%, and grapefruit seed extract 0.35%.
Salso-bromo-iodine thermal water may exert 
some relevant therapeutic effects, including enhanc-
ing the mucociliary clearance, anti-edema activity, and 
washing effect (12). HA is a fundamental component 
of the connective tissue. HA is able to modulate in-
flammatory response, cellular proliferation, and re-
modeling of extracellular matrix (13). Grapefruit seed 
extract exerts an antimicrobial activity (14).
Recently, it has been reported that Broncalt® was 
effective in the treatment of postnasal drip-related 
cough in children with upper respiratory tract infec-
tions (15).
On the basis of this background, an Italian survey 
explored the pragmatic approach of a group of otolar-
yngologists in the management of acute upper-airways 
disorders in clinical practice. Therefore, the aim of the 
current survey was to evaluate the efficacy and safety 
of Broncalt® in outpatients with acute ORL diseases.
Materials and Methods
The current survey was conducted in 84 Italian 
ORL centers, distributed in the whole Italy, so assur-
ing a wide and complete national coverage. Otolaryn-
gologists were asked to recruit all consecutive patients 
visited because of acute respiratory ORL disease.
Patients were consecutively recruited during the 
specialist visit. The inclusion criteria were: to have a 
diagnosis of acute respiratory ORL disease, both gen-
ders, and adulthood. Exclusion criteria were to have 
comorbidities and concomitant medications able to 
interfere the evaluation of outcomes. 
As this survey was based on a real-world practice, 
the doctors had the complete liberty of choosing the 
preferred medications on the basis of the personal best 
practice. Actually, patients were subdivided in 2 sub-
groups: i) patients treated with standard therapy plus 
Broncalt® (active group), and ii) patients treated with 
standard therapy alone (control group).
Patients were suffering from acute illness, in-
cluding common cold, acute rhinosinusitis, acute rhi-
nopharyngitis, acute pharyngitis, acute otitis, bacterial 
tonsillitis, acute laryngitis or acute laryngotracheitis.
All patients signed an informed consent. All the 
procedures were conducted in a real-world setting.
The treatment course lasted 2 weeks. The medi-
cal device Broncalt® (Aurora Biofarma, Milan, Italy) 
was taken following the specific indications, such as 
two tablets/daily. Patients were visited at baseline (T0), 
after 1-week treatment (T1), and after 2-week treat-
ment (T2).
Clinical examination and fiber-endoscopy were 
evaluated in all patients at all visits. 
All clinical data were inserted in an internet-plat-
form that guaranteed the patients’ anonymity and the 
findings’ recording accuracy. 
The following clinical parameters were evaluated: 
nasal obstruction, mucosal edema, hyperemia, earache, 
nose swelling, sore throat, dysphonia, and cough. These 
issues were considered both as the quote of patients 
having them and their perceived severity. Symptom 
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severity was assessed by a visual analogue scale (VAS). 
VAS is a psychometric test widely used to measure the 
patient’s perception of symptom severity, emotions, 
pain, etc. Currently, VAS is a reliable and valid tool 
to assess the perception of symptoms and signs (16). 
The VAS consisted of one ruler asking for signs and 
symptoms severity perception. In this study, the VAS 
was a 10-cm horizontal line on which 0 implied the 
absence of sing or symptom, while 10 corresponded 
to maximal severity. VAS is considered a routine and 
validated parameter to assess disease severity in clinical 
practice and inflammatory markers are closely related 
with nasal obstruction perception (17). 
In addition, the symptom disappearance duration 
was also considered, such as 3 period were established 
for symptom receding: by 3 days, between 4-7 days, 
and beyond 7 days.
Doctors also evaluated: the effectiveness (scored 
as very effective, effective, scarcely effective, and in-
effective), the tolerability (scored as very good, quite 
good, poorly good, no good), and the compliance (very 
good, good, scarcely good, and no good).
Safety was measured by reporting the occurrence 
of adverse events.
The paired T-test was used. Statistical significance 
was set at p <0.05. Data are expressed as medians and 
1th and 3rd quartiles. The analysis was performed using 
STATA, College Station, Texas, USA. 
Results
Globally, 3,533 (1,797 males, mean age 43.5 
years) patients were visited and completed the treat-
ment course. The demographic characteristics and type 
of acute respiratory disease are reported in Table 1.
In particular, the two subgroups were similar 
concerning the age and the gender. The distribution 
Table 1. Clinical characteristics in patients with acute respiratory disease and treated with or without Broncalt
 Broncalt No Broncalt p-value
 N=2784 N=749
Demografic characteristics
Males, n(%) 1406 50.5% 391 52.2% 0.409
Mean age, years, (SD) 43.6 20.9 43.4 18.4 0.432
Disease     
Otitis, n(%) 408  14.7% 137 18.3% 0.014
Tubaritis, n(%) 359 12.9%   79 10.6% 0.084
Rinosinusitis, n(%) 604 21.7% 129 17.2% 0.007
Rinopharyngitis, n(%) 652 23.4% 107 14.3% <0.001
Bacterial Tonsillitis, n(%) 165   5.9% 108 14.4% <0.001
Pharingytis, n(%) 365 13.1% 144 19.2% <0.001
Laryngitis, n(%) 338 12.1% 102 13.6% 0.277
Laryngotracheitis, n(%) 196   7.0%   49 6.5% 0.634
  
Concomitant Tretaments 
Antibiotics   280 10.0% 199 26.6%
     Cefalosporins   197   7.1% 119 15.9%
     Chinolones     26   0.9%   31   4.1%
     Macrolides     26   0.9%   30   4.0%
     Other     31   1.1%   19   2.5%
Anti-inflammatory drugs   484 17.4% 221 29.5%
     Antipyretics     11   0.4%   10   1.3%
     Corticosteroids   368 13.2% 101 13.5%
     FANS     44   1.6%   76 10.1%
     Other     61   2.2%   34   4.5%
Anti-inflammatory+antibiotic   212   7.6% 312 43.3%
No drug 1808 64.9%   17   2.2%
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of acute respiratory diseases was different about some 
types. Subgroup treated with Broncalt took less an-
tibiotics and anti-inflammatory drugs than the other 
subgroup; interestingly Broncalt-treated subgroups 
did not take any medication more frequently.
Considering the frequency of patients without 
symptoms or signs after the treatment, Broncalt treat-
ment induced higher percentages of symptomless pa-
tients for nasal obstruction, rhinorrhea, post nasal drip, 
nose swelling, cough, and hyperemia (Table 2). On the 
contrary, a larger percentage of patients not treated 
with Broncalt had no more sore throat and edema.
Considering the severity of symptoms, patients 
treated with Broncalt showed less severe earache and 
sore throat than not treated patients (Figure 1).
The percentages of patients treated with or without 
Broncalt with global symptom disappearance within 3 
days, and over 7 days were significantly different be-
tween groups (Figure 2). In particular, 54.6% of Bron-
calt-treated patients and 35% of patients without Bron-
calt treatment had no more symptoms within 3 days 
(p<0.001). On the contrary, 38.7% of patients without 
Broncalt treatment and 16.1% of Broncalt-treated pa-
tients still present symptoms over one week (p<0.001).
Table 2. Proportion of patients without symptoms and signs 
after treatment in the two subgroups: treated with or without 
Broncalt
Symptom Broncalt No Broncalt  P
Nasal Obstruction 48.4% 28.8% <0.001
Rhinorrea 44.3% 28.3% <0.001
Post nasal drip  32.7% 19.4% <0.001
Earache 26.2% 24.6% 0.369
Nose swelling 33.3% 23.1% <0.001
Sore throat 27.1% 33.1% 0.001
Dysphonia 22.5% 21.8% 0.688
Cough 39.9% 34.5% 0.006
Hyperaemia 55.2% 50.3% 0.017
Edema 25.3% 32.7% <0.001
Figure 1. Visual Analogue Scale scores at T0 and T1 in patients treated with or without Broncalt for Earache and Sore throat
Figure 2. Percentages of patients treated with or without Bron-
calt with symptom disappearance within 3 days, between 3 and 
7 days, and over 7 days
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In patients treated with Broncalt, the perception 
of efficacy was very good in 88.2% and good in 10.4% 
(Figure 3A); the tolerability was very good in 89.2% 
and good in 9.9% (Figure 3B); the compliance was 
very good in 88.2% and good in 10.4% (Figure 3C).
No clinically relevant adverse event was reported.
Discussion
The role of natural non-pharmacological products 
as remedies has been respected since ancient times. At 
present, there is popular and scientific interest in the 
use of medical device to improve human diseases, so 
sparing the use of conventional medications. In spite 
of major scientific and technological progress in com-
binatorial chemistry, products derived from natural 
products, including thermal water, still make an enor-
mous contribution to medication discovery today. 
Inflammatory reaction is a common pathway in 
acute infectious ORL disorders. In this regard, the 
medical device Broncalt® contains 3 main components: 
salso-bromo-iodine thermal water, HA, and grapefruit 
seed extract. All of them provide anti-inflammatory, 
antimicrobial, and washing properties. Consequently, 
this medical device seems to be indicated in the acute 
ORL respiratory disorders as recently reported (15).
The current survey demonstrated that Broncalt® 
treatment significantly improved the clinical feature. 
In particular, Broncalt significantly reduced the per-
centage of patients still reporting symptom occurrence 
after the treatment and the symptom severity. Interest-
Figure 3. A= Patients’ perception of Broncalt efficacy; B= Patients’ perception of Broncalt tolerability; C= Patients’ perception of 
Broncalt Compliance.
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ingly, the Broncalt treatment induced a faster disap-
pearance of symptoms as more than 50% of patients 
had no more symptoms already within 3 days after the 
start of the treatment.
The present findings are consistent with previous 
studies that explored the therapeutic effects of similar 
multi-component nutraceuticals in the treatment of 
ORL diseases (12-15). 
In addition, it has to be mentioned that upper 
airways are closely linked with lower ones, so, these 
outcomes could have a clinical relevance if there is a 
lower respiratory co-morbidity (18, 19).
Therefore, the present survey confirms that Bron-
calt® may significantly reduce clinical features in acute 
ORL diseases characterized by an infectious/inflam-
matory reaction. However, the current experience has 
some limitations, mainly concerning the open design 
and the lack of objective functional data. On the other 
hand, the strength of this survey is the high number 
of enrolled patients and the real-world setting, so the 
findings may mirror what occurs in the daily practice.
In conclusion, the present survey evidenced that 
Broncalt® may induce a safe control of respiratory 
complaints in acute ORL disorders.
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